We recently demonstrated that expression of ADP-ribosylation factor (ARF)-like 4c (Arl4c) induced by a combination of Wnt/β-catenin and epidermal growth factor/Ras signaling in normal epithelial cells grown in three-dimensional culture promotes cellular migration and proliferation, resulting in formation of tube-like structures, suggesting the involvement of Arl4c in epithelial morphogenesis. It is conceivable that there could be a common mechanism between epithelial morphogenesis and carcinogenesis. Therefore the current study was conducted to investigate whether Arl4c might be involved in tumorigenesis. Immunohistochemical analyses of tissue specimens obtained from colorectal and lung cancer patients revealed that Arl4c was not observed in non-tumor regions but was strongly expressed at high frequencies in tumor lesions. Inhibition of Wnt/β-catenin or Ras/mitogen-activated protein kinase signaling reduced Arl4c mRNA levels in HCT116 colorectal cancer cells and A549 lung cancer cells. Knockdown of Arl4c inhibited Rac activity and also prevented nuclear localization of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) in these cancer cells. Arl4c-depleted cancer cells consistently showed decreased migration, invasion and proliferation capabilities both in vitro and in vivo. Furthermore, direct injection of Arl4c small interfering RNA (siRNA) into HCT116 cell-derived tumors (in vivo treatment with siRNA) inhibited tumor growth in immunodeficient mice. These results suggest that Arl4c is involved in tumorigenesis and might represent a novel therapeutic target for suppressing proliferation and invasion of colorectal and lung cancer cells.
INTRODUCTION
Most malignant tumors in humans arise from epithelial tissues, which exhibit unique characteristics, including apical and basolateral polarization, cell-to-cell contact between neighboring cells and anchoring to a basement membrane. Additionally, epithelial tissues usually display a well-ordered and less proliferative architecture. 1 Epithelial cells grown in a three-dimensional (3D) culture form cyst-like spheroids with a hollow lumen and demonstrate tight control of cell proliferation. Growth factor signaling causes these normal cells to exhibit behavior similar to cancer cells by migrating and proliferating in 3D culture. 2 We recently found that the expression of ADP-ribosylation factor (ARF)-like 4c (Arl4c) was induced by simultaneous activation of the Wnt/β-catenin and epidermal growth factor (EGF)/Ras signaling pathways during the process of epithelial tubulogenesis in rat intestinal epithelial cells (IEC6) grown in 3D culture with Matrigel (3D Matrigel). 3 Arl is a small GTP-binding protein that belongs to an ARF subfamily of proteins. 4, 5 There are eight proteins in the Arl family, and Arl4c was isolated by searching the EST database and performing 5′-Rapid Amplification of cDNA Ends. 6 Although it is known that Arl4c stimulates cholesterol efflux in HeLa cells 7 and is involved in transport of transferrin from early endosomes to recycling endosomes by interacting with α-tubulin in human renal carcinoma cells, 8 the detailed modes of Arl4c activation and action are not well understood. During epithelial tubule formation, Wnt3a and EGF signaling pathways synergistically induce Arl4c expression, which then activates Rac1 through Arf6 and inhibits Rho. This results in nuclear localization of a transcriptional activator, yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ), to stimulate cell proliferation. Thus Arl4c expression induces cell morphological changes and also promotes cellular migration and proliferation, thereby inducing epithelial tube formation in 3D Matrigel. Arl4c is also expressed in the tips of ureteric buds of embryonic kidney, and manipulations to suppress Arl4c expression inhibit ureteric bud formation (numbers and sizes). 3 Therefore it is possible that Arl4c induces motility and proliferation of epithelial cells in the extracellular matrix during the formation of tube-like structures.
Abnormalities in Wnt and EGF signaling are involved in various cancers, 9 and mutations in the adenomatous polyposis coli (APC) gene are observed in most cases of sporadic colorectal cancer. 10, 11 A loss of APC functions stabilizes β-catenin by disrupting the Axin complex and allows β-catenin to associate with transcription factors T-cell factor/lymphoid enhancer factor (Tcf/Lef) in the nucleus. This association induces the expression of various genes, including c-Myc and cyclin D1. 12 Point mutations in the β-catenin gene that result in the loss of amino acids necessary for its degradation occur in some colorectal and liver carcinomas, 10 while point mutations in the KRas gene and overexpression of HER/neu are often detected in lung adenocarcinoma. 13 These genetic alterations result in persistent activation of the Ras/mitogen-activated protein kinase (MAPK) pathway to induce gene expression through transcription factors Ets or Elk. 9 We found that Ets constitutively binds to the 3′ non-coding region of the Arl4c gene and that a combination of Wnt3a and EGF induces formation of a complex between Ets, β-catenin and Tcf4, thereby inducing Arl4c mRNA expression through enhancement of histone H3 acetylation. 3 Additionally, overexpression of mutated β-catenin and Raf, a direct effector of Ras, indeed increased the Arl4c expression. Based on these results, we examined whether Arl4c might be expressed in cancer cells where Wnt and Ras/MAPK signaling are activated constitutively. Here we report that Arl4c was expressed in the tumor lesions but not in the non-tumor regions of colorectal and lung cancers. We also demonstrated that Arl4c was involved in tumor cell growth both in vitro and in vivo and suggest that in vivo treatment with Arl4c small interfering RNA (siRNA) contributes to the development of a novel anticancer medicine.
RESULTS

Arl4c is expressed in human colorectal and lung cancers
In specimens of colorectal cancer, non-tumor epithelium contained no Arl4c-positive cells, whereas tumor lesions showed cytoplasmic staining for Arl4c expression ( Figure 1a ). Because in some cases the tumor lesions showed only a small area of Arl4c expression, the stained areas were classified into four categories (o 5, 5-20, 20-50 and 50-95%) ( Figure 1a and Supplementary Figure S1A ). Results were considered positive when the total area of a tumor lesion showed 45% staining. In total, 55 of the 117 colorectal cancer cases (47%) were positive for the Arl4c expression. The positivity and the size of the area showing Arl4c expression were not correlated with the T grade (depth of invasion) or N grade (degree of lymph node metastasis) of the tumor ( Table 1 ), suggesting that Arl4c expression is specifically involved in initiation of tumor formation. Metastatic cancer cells in lymph nodes stained positive for Arl4c expression more frequently than primary tumor lesions ( Figure 1b ), suggesting that Arl4cpositive cancer cells might tend to invade and grow in distant metastatic lesions.
Arl4c expression was also examined in cases of lung adenocarcinoma. Arl4c-postive cells were never observed in the alveolar epithelium of non-tumor regions, whereas tumor lesions showed Arl4c expression ( Figure 1c ). Arl4c was expressed in larger areas of adenocarcinoma lesions compared with the expression in colorectal cancer lesions (Figure 1c and Supplementary Figure S1B ). In total, 51 of the 65 lung adenocarcinoma cases (78.5%) stained positive for the Arl4c expression, and similar to colorectal cancer, the positivity of Arl4c expression was not correlated with the tumor's T grade or N grade ( Table 2 ). It is also noteworthy that Arl4c expression was observed in 8 of the 9 patients with atypical adenomatous hyperplasia (AAH), which is a putative precursor lesion of adenocarcinoma ( Figure 1d ). AAH cells proliferate along the preexisting alveolar epithelial framework and show atypical features, such as cuboidal increased cell size and prominent nucleoli; additionally, the grade of atypia associated with AAH is usually milder than that associated with adenocarcinoma. 14 
Arl4c expression is involved in migration and invasion of cancer cells
Arl4c mRNA expression was examined in several cell lines derived from colorectal and lung cancers (Supplementary Figure S2A ). HCT116 and DLD-1 colorectal cancer cells exhibit genetic mutations in β-catenin and Ras 15 and in APC and Ras, 16, 17 respectively. A549 and NCI-H358 lung adenocarcinoma cells are known to harbor a Ras mutation. 18, 19 These cancer cells show high levels of Arl4c mRNA expression compared with uterine cancer HeLaS3 cells. HCT116 and A549 cells showed decreased expression of Arl4c mRNA by knockdown of β-catenin or treatment with the MEK inhibitor, U0126 (Supplementary Figure S2B ). Additionally, treatment with a Wnt secretion inhibitor (IWP2) 20 also suppressed Arl4c mRNA expression in A549 cells (Supplementary Figure S2B ), suggesting that endogenous Wnt activates the β-catenin pathway and is involved in Arl4c expression in A549 cells. Thus Arl4c is transcriptionally activated by both the Wnt/β-catenin and the Ras/MAPK pathways in these cancer cells.
Knockdown of Arl4c expression by two independent siRNAs decreased Arl4c mRNA and protein levels (Supplementary Figures  S3A and B) , and both siRNAs inhibited HCT116 and A549 cell migration and invasion capabilities ( Supplementary Figures S3C  and D) . Because Arl4c #1 siRNA targets the 3′-untranslated region of Arl4c mRNA, it did not decrease the amount of exogenously expressed Arl4c-GFP (green fluorescent protein) in these cancer cells ( Supplementary Figures S3E and F) . Because the degradation products of exogenously expressed Arl4c-GFP were present in HCT116 cells, western blotting failed to detect the decrease of endogenous Arl4c (Supplementary Figure S3E ). Therefore the effect of Arl4c #1 siRNA was confirmed by quantitative real-time PCR, which showed that endogenous Arl4c mRNA levels were indeed decreased by Arl4c #1 siRNA using primers encoding 3′-untranslated region (Supplementary Figure S3E ). Cancer cells expressing Arl4c-GFP and GFP showed the similar migration and invasion capabilities (Figures 2a-d ), suggesting that endogenous Arl4c is sufficient to regulate the abilities of HCT116 and A549 cells. The inhibitory phenotypes of Arl4c #1 siRNA were rescued by exogenous Arl4c-GFP expression, excluding siRNA off-target effects (Figures 2a-d ). Based on these results, target sequences of Arl4c #1 shRNA were designed to be identical to those of Arl4c #1 siRNA and used in the following experiments.
HCT116 and A549 cells stably expressing Arl4c #1 shRNA were generated to constitutively reduce the levels of endogenous Arl4c (Figure 3a ). The inhibition of migration capability was confirmed using the wound-healing assay in Arl4c-depleted cancer cells, but adhesion activity was not affected (Figures 3b and c) . Therefore Arl4c might be involved mainly in migration and invasion rather than adhesion. These results are consistent with the findings that knockdown of Arf6, a possible downstream effector of Arl4c, suppresses migration but not adhesion activity in breast cancer cells. 21 Arl4c expression activates Rac1 and inhibits Rho in IEC6 cells. 3 It was reported that coordinate work of Rac1 and Rhokinase promotes glioma invasion. 22 Accordingly, Rac activity was inhibited ( Figure 3d ) and Rho activity was increased ( Figure 3e ) in HCT116 and A549 cells stably expressing Arl4c #1 shRNA, suggesting activation of the Arl4c-Rac-Rho axis in Arl4cexpressing cancer cells and the subsequent promotion of the migration and invasion activities of these cancer cells.
Arl4c expression is required for cancer cell proliferation Constitutive depletion of Arl4c in HCT116 and A549 cells did not affect their growth on a two-dimensional (2D) plastic dish ( Figures  4a and b) . In contrast, when HCT116 and A549 were grown in 3D Matrigel, knockdown of Arl4c reduced sphere areas of tumor by 50% (Figures 4c and d ). In addition, knockdown of Arl4c suppressed nuclear incorporation of the cell proliferation marker, EdU (5-ethynyl-2′-deoxyuridine; Figures 4c and d) . These results suggest that Arl4c may favor tumor formation by increasing invasive growth into stromal tissue. Arl4c promotes IEC6 cell proliferation by inducing the nuclear localization of transcription activators YAP/TAZ. 3 YAP/TAZ were observed in the nuclei of control shRNA expressing A549 cells cultured in 3D Matrigel and were also distributed throughout the cytoplasm of Arl4c-depleted A549 cells ( Figure 4e ). Consistent with these findings, the mRNA levels of connective tissue growth factor (CTGF) and ankyrin repeat domain1 (ANKRD1), which are target genes of YAP/TAZ, were reduced in Arl4c-depleted HCT116 and A549 cells (Figure 4 f). Expression of an active YAP mutant FLAG-YAP 5SA , in which five possible phosphorylation serine residues are changed to alanine, 3 enhanced the sphere formation ( Supplementary Figures S4A  and B ) and YAP/TAZ target gene expression ( Supplementary  Figures S4C and D) and rescued the phenotypes induced by Arl4c depletion. These results confirm that YAP/TAZ act downstream of Arl4c. In human cancer cases, YAP/TAZ were observed in approximately 36% and 53% of the nucleus of Arl4c-positive lesions in colorectal and lung cancers, respectively, and it was not detected in the remaining lesions ( Supplementary Figures S5A  and B ). In addition, YAP/TAZ were also detected in approximately 36% and 50% of the nucleus of Arl4c-negative lesions in colorectal and lung cancers, respectively ( Supplementary Figures S5A and B) .
These results suggest that Arl4c regulates the signaling cascade other than YAP/TAZ to induce tumor formation in vivo and that YAP/TAZ nuclear localization is regulated in Arl4c-dependent and -independent manners.
The role of Arl4c expression in tumorigenesis in vivo was investigated by subcutaneously implanting cancer cells into the flanks of nude mice. Although HCT116 and A549 cells stably expressing Arl4c #1 shRNA demonstrated growth in vivo, the volumes and weights of the xenograft tumors derived from those cells were less than the volumes and weights of control tumors (Figures 5a and b ). Immunohistochemical analyses performed on xenografts harvested at the end of the experiment showed that knockdown of Arl4c indeed reduced the numbers of Arl4c-positive cells in tumors; additionally, the numbers of Ki-67-positive cells were also decreased in Arl4c-depleted tumors (Figures 5c and d) .
These results suggest that Arl4c expression is required for tumor formation in vivo.
Inhibition of xenograft tumor proliferation by in vivo treatment with Arl4c siRNA
We examined Arl4c as a potential target for cancer therapy. HCT116 cells were implanted into nude mice, and tumors were allowed to develop for 3 days (tumor diameter is~4 mm). Next, control or Arl4c #1 siRNA was mixed with atelocollagen to facilitate siRNA introduction into cancer cells in tissue, and the mixture was injected once around the base of each xenograft tumor. 23, 24 Tumor development was continued for additional 10 days. Such in vivo treatment with Arl4c siRNA reduced the volumes and weights of the tumors (Figure 6a ) and also clearly decreased the Arl4c mRNA levels in xenografts compared with levels in tumors injected with control siRNA (Figure 6b ). Immunohistochemical analyses also showed that Arl4c-positive and Ki-67-positive cell numbers were decreased in the Arl4c #1 siRNA-injected tumors (Figures 6b and c) . Among the 10 mice tested, 7 mice showed anti-tumor effects by in vivo treatment with Arl4c #1 siRNA as described above, but the remaining 3 mice did not show decrease in Arl4c mRNA levels and tumor volumes (data not shown). In another set of experiment, when siRNAs were injected into the developed tumors at 9 days after implantation (tumor diameter is~7 mm), two of the four mice showed decreased tumor volumes and weights (Supplementary Figure S6A ) and the Arl4c mRNA levels (Supplementary Figure S6B ), but the remaining mice did not show changes in the tumors and the Arl4c mRNA levels (data not shown). Therefore in vivo treatment with Arl4c siRNA reduced Arl4c mRNA levels, and tumor sizes were decreased, suggesting Arl4c as a target for cancer therapy.
DISCUSSION
Involvement of Arl4c expression in tumorigenesis
In this study, we showed that Arl4c was overexpressed in 50-70% of colorectal and lung cancer cases. In normal cultured epithelial cells (for example, IEC6 cells), Arl4c expression is induced by cooperative signaling of Wnt3a/β-catenin and EGF/Ras-MAPK. 3 Therefore it is reasonable that Arl4c expression is increased in tumors where genetic alterations in APC, β-catenin and Ras are frequently observed, and the Wnt and EGF signaling pathways are activated.
Although Arl4c belongs to the Ras-like small G protein superfamily, its regulators, GDP/GTP exchange factor(s) (GEF) and GTPase activating protein(s) (GAP), have not been characterized. Wild-type Ras usually exists in a GDP-bound inactive form. Ras mutants in which Gly13 is mutated to Asp (or Gln61 is mutated to Leu) observed in tumors do not require GEF to become the GTP-bound form or interact with GAP to become the GDP-bound form, 25 indicating that Ras mutants are a constitutively active form. Biochemical analyses revealed that Arl4c had the considerably higher GTP-binding activity in the presence of a mM order of MgCl 2 concentration, 5, 6 suggesting that wild-type Arl4c is a GTP-bound active form without inherent stimulation capabilities. In fact, wild-type Arl4c and its GTP-bound form (Arl4c Q72L ) 8 show similar efficiencies for interacting with a putative effector protein of Arl4c, ARNO. 26, 27 Although we do not know whether overexpressed Arl4c is mutated, once Arl4c is expressed, even though it may be a wild type, it may activate downstream signaling. Thus Arl4c activity might be regulated by its expression levels rather than switches between GDP-and GTP-bound states induced by regulators.
Arl4c expression was not associated with the T grade and N grade of either colorectal or lung cancers, suggesting its involvement in the initiation rather than progression of colorectal and lung cancers. Furthermore, Arl4c was also detected in lung AAH, suggesting its involvement of the precancerous state of the lung. It is noteworthy that Arl4c was detected with a high frequency in colorectal and lung tumor lesions, whereas no positive signal was detected in the non-tumor regions, suggesting that Arl4c might be a highly specific marker for these cancers.
Experiments with knockdown of Arl4c revealed that Arl4c expression was involved in activation of Rac, inhibition of Rho and the nuclear localization of YAP/TAZ, leading to cancer cell invasion and growth. These results are consistent with our previous observations made in studies examining tubule formation from IEC6 cells stimulated with Wnt3a and EGF. 3 Evidence has been accumulated that YAP/TAZ have important roles in tumorigenesis. 28, 29 YAP indeed rescued the phenotypes of Arl4cdepeleted cancer cells in vitro. However, in our clinical samples YAP/TAZ were observed in approximately 30-50% of the nucleus of Arl4c-positive cancer lesions, suggesting that Arl4c expression Abbreviations: Tis, tumor confined to mucosa; T1, tumor invading submucosa; T2, tumor invading muscularispropria; T3, tumor invading subserosa; T4, tumor invading adjacent organs or perforates the visceral peritoneum; N0, no regional lymph node metastasis; N1, metastasis in 1-3 regional lymph nodes; N2, metastasis in ⩾ 4 regional lymph nodes; N3, distant metastasis. Abbreviations: T1, tumor's greatest dimension is o3 cm, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus; T2, tumor 43 cm but o7 cm; T3, tumor 47 cm; N0, no regional lymph node metastasis; N1, metastasis in ipsilateral, peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension; N2, metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s).
Arl4c expression in colorectal and lung cancers S Fujii et al induces tumor formation in YAP/TAZ-dependent and -independent manners. Thus it is possible that regulated expression of Arl4c might be required for epithelial tubulogenesis, while unregulated Arl4c expression induced by abnormal activation of Wnt/β-catenin and EGF/Ras signaling may lead to tumor formation. In addition to genetic changes, epigenetic modifications may also have important roles in tumorigenesis. 30 Arl4c was found to be upregulated and hypomethylated in thymocyte progenitors during their lineage-specific differentiation from hematopoietic progenitors. 31 Therefore it is intriguing to speculate that Arl4c expression might be induced by hypomethylation in tumors that do not have genetic alterations in the components of Wnt/β-catenin and EGF/Ras signaling.
Implications of Arl4c as a novel therapeutic target for cancer
Various components of the Wnt and EGF signaling pathways represent potential targets for anti-cancer therapy. Gefinitib, which blocks the kinase activity of EGF receptor mutants, is the therapeutic drug of choice for lung cancer, 32 whereas only a few targets suitable for drug intervention have been reported in Wnt signaling. 33, 34 Overexpression of Arl4c did not promote proliferation of cancer cells in 2D culture conditions, but did promote proliferation in 3D culture and in vivo, suggesting that Arl4c may increase invasive growth into stromal tissue, and thereby contribute to tumor formation. Because there could be a common mechanism between organ formation by embryonic cells and tumor formation by cancer cells, 35 screening methods used to identify molecules that regulate normal epithelial morphogenesis in 3D culture might prove reliable for identifying new oncogenes and tumor-suppressor genes. Direct injection of Arl4c siRNA into HCT116 cell-derived xenograft tumors suppressed their proliferation in nude mice, suggesting that Arl4c might be a novel therapeutic candidate for at least colorectal and lung cancers. Although siRNA has recently been recognized as promising and potent medicine for treatment of several human diseases, including cancer, 36 its use in clinical therapy has been hindered by drug delivery hurdles, and development of carefully designed delivery methods is required. In fact, our experiments using in vivo treatment with Arl4c siRNA failed to decrease Arl4c mRNA in some cases probably due to incomplete introduction of siRNA into xenograft tumors.
In summary, we found that Arl4c was overexpressed in tumor lesions of colorectal and lung cancers with high frequencies. We also demonstrated that Arl4c expression promoted migration, invasion and proliferation of cancer cells both in vitro and in vivo. Furthermore, direct injection of Arl4c siRNA into HCT116 cellderived xenograft tumors suppressed tumor growth. These results suggested that Arl4c might represent a novel therapeutic target for colorectal and lung cancers with Arl4c overexpression. The ages of the patients ranged from 28 to 86 years (median, 68 years). Tumors were staged according to the International Union Against Cancer TNM staging system. Resected specimens were macroscopically examined to determine the location and size of a tumor, and specimens for histology were fixed in 10% (v/v) formalin and processed for paraffin embedding. Paraffinembedded specimens were stored at room temperature in a dark room located at the Department of Pathology of Osaka University Hospital. Specimens for examination were sectioned at 4-μm thickness and stained with hematoxylin and eosin or immunoperoxidase for independent evaluations by two pathologists (SN and EM) . The protocol for this study was approved by the ethical review board of the Graduate School of Medicine, Osaka University, Japan (No. 13032).
MATERIALS AND METHODS
Patients and cancer tissues
Immunohistochemical studies of Arl4c and YAP/TAZ in colorectal and lung adenocarcinoma tissues in accordance with the manufacturer's recommendations. 37 Antigen retrieval for staining was done using a decloaking chamber (Biocare Medical, Walnat Creek, CA, USA). Tissue peroxidase activity was blocked with 3% H 2 O 2 -methanol for 15 min, and the sections were then incubated with goat serum for 1 h to block nonspecific antibody-binding sites. Tissue specimens then were incubated with anti-Arl4c antibody (1:100) or anti-YAP/TAZ antibody (1:100) for 10 or 16 h, respectively, at 4°C, and binding was detected by subsequent incubation with goat anti-rabbit immunoglobulin G (IgG)-horseradish peroxidase for 1 h. Diaminobenzidine (Dako) was used as a chromogen. The tissue sections were then counterstained with 0.1% (w/v) hematoxylin. Tumors in which the positively stained area covered 45% or 425% of the lesion were classified as Arl4c-positive or YAP/TAZ-positive, respectively. 38 Cells and antibodies HCT116 and DLD-1 colorectal cancer cells were kindly provided by Dr T Kobayashi and Dr W Yasui (Hiroshima University, Hiroshima, Japan), respectively. A549 and NCI-H358 lung adenocarcinoma cells were obtained from Dr Y Shintani (Osaka University, Suita, Japan). HeLaS3 uterine cancer cells were provided from Dr K Matsumoto (Nagoya University, Aichi, Japan). X293T cells were purchased from Takara Bio Inc. (Shiga, Japan). Antibodies used in this study are described in Supplementary Table S1 .
Xenograft tumor assay
Five-week-old male BALB/cAnNCrj-nu nude mice (Charles River Laboratory Japan Inc., Osaka, Japan) were anesthetized with a combination of medetomidine (0.3 mg/kg body weight) and midazolam (4 mg/kg). The mice then received a dorsal subcutaneous injection of HCT116 (1 × 10 6 cells) or A549 (5 × 10 6 cells) cells suspended in 100 μl phosphate buffered saline (PBS). 39, 40 The nude mice were then killed at 14 days (for HCT116 cells) or 38 days (for A549 cells) after transplantation, and the areas containing transplanted cells were measured, weighed and processed for immunohistochemical analyses. Tumor volumes were calculated using the following formula: (major axis) × (minor axis) × (minor axis) × 0.5. 40 All protocols used for all animal experiments in this study were approved by the Animal Research Committee of Osaka University, Japan (No.2867).
In vivo siRNA treatment HCT116 cells (1 × 10 6 ) suspended in 100 μl of PBS were subcutaneously injected into the dorsal surfaces of 5-week-old male BALB/cAnNCrj-nu nude mice that had been previously anesthetized. Three days after implantation, the developed tumors were treated with control siRNA or Arl4c siRNA together with atelocollagen (AteloGene, KOKEN, Tokyo, Japan) to facilitate siRNA introduction into tumors. A 200-μl volume of siRNA solution (30 μmol/l in 0.5% (v/v) atelocollagen) was injected directly once around the base of each tumor as previously described. 23 
Knockdown of protein expression by siRNA
The effects of protein knockdown by siRNA were analyzed as previously described. 3 Target sequences are listed in Supplementary Table S2 . HCT116 and A549 cells were transfected with a mixture of siRNAs (20 nM each) against genes of interest using RNAiMAX (Invitrogen, Carlsbad, CA, USA). The transfected cells were then used for experiments conducted at 36-48 h posttransfection.
Plasmid construction and infection using lentivirus harboring a cDNA or shRNA pEGFPN3-Arl4c and FLAG-YAP 5SA were constructed as previously described. 3 Lentilviral vectors were constructed by subcloning GFP and pEGFPN3-Arl4c cDNAs into CSII-CMV-MCS-IRES2-Bsd (kindly provided by Dr H Miyoshi (RIKEN BioResource Center, Ibaraki, Japan). 41 To construct a lentivirus vector harboring shRNA, a DNA fragment containing the H1 promoter and shRNA was cloned into CS-RfA-EVBsd using the Gateway technology (Invitrogen). Target sequences are listed in Supplementary  Table S2 . The vectors were then transfected with the packaging vectors, pCAG-HIV-gp and pCMV-VSV-G-RSV-Rev, into X293T cells using FuGENE HD transfection reagent (Roche Applied Science, Basel, Switzerland) to generate lentiviruses. To generate HCT116 and A549 cells that stably expressed Arl4c-GFP or Arl4c shRNA, parental cells (5 × 10 4 cells/well in a 12-well plate) were treated with lentivirus and 10 μg/ml polybrene. The cells were then centrifuged at 1200 g for 1 h and incubated for another 24 h. The incubated cells demonstrating stable expression of Arl4c-GFP or Arl4c shRNA were selected and maintained in culture medium containing 5 μg/ml Blasticidin S.
Immunohistochemical study of xenograft tumors
Xenograft tumors derived from HCT116 or A549 cells were fixed in 10% (v/v) formalin and processed for paraffin embedding. Specimens for examination were sectioned at 5-μm thickness and stained with hematoxylin and eosin or immunoperoxidase. Tissue sections for immunohistochemical staining for Arl4c were examined using a DakoReal EnVision Detection System.
After nonspecific binding were blocked in PBS containing 0.5% (w/v) Triton X-100 and 4% (w/v) bovine serum albumin for 30 min, the sections were incubated with anti-Ki-67 antibody (1:300) for 3 h at room temperature and incubated with goat Alexa488 conjugated anti-mouse IgG (Invitrogen) (1:300) for 2 h. The sections were then counterstained with DRAQ5, and the numbers of Ki-67-positive cells or DRAQ5-stained cells were counted.
Statistical analysis
Statistical analyses were performed using the JMP software (SAS Institute Inc., Cary, NC, USA). Differences in results were tested for statistical significance using the Fisher's exact test for Tables 1 and 2, Mann-Whitney U test for the volumes and weights of xenograft tumors, Student's t-test for other experiments, and P-values o 0.01 or o0.05 were considered statistically significant.
Additional assays 3D Matrigel culture of HCT116 and A549 cells, EdU nuclear incorporation and immunocytochemical study using anti-YAP/TAZ antibody were performed as previously described. 3 Rac and Rho activities were assayed as described. 42, 43 Quantitative real-time PCR, cell proliferation, adhesion, migration and invasion assays were performed as described. [44] [45] [46] [47] Forward and reverse primers for quantitative real-time PCR used in this study are shown in Supplementary Table S3 . Western blotting data are representative of at least three independent experiments.
